NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Nyxoah said the FDA approved the company's Genio system for a subset of patients with moderate to severe obstructive sleep apnea. The system includes a wearable component, which provides patients with ...

“The DREAM study demonstrated efficacy of bilateral hypoglossal nerve stimulation using Genio for the treatment of obstructive sleep apnea," said B. Tucker Woodson, MD, Chief, Professor ...

DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...